 |
市场调查报告书
商品编码
1461309
PD-1 和 PD-L1 抑制剂市场、按抑制剂类型、按癌症类型、按配销通路、按地理区域PD-1 and PD-L1 Inhibitor Market, By Type of Inhibitor, By Cancer Type, By Distribution Channel, By Geography |
||||||
价格
简介目录
PD-1和PD-L1抑制剂市场预计2024年价值525.1亿美元，预计到2031年将达到1,700.1亿美元，2024年至2031年年复合成长率（CAGR）为18.3%。
| 报告范围 | 报告详情 | ||
|---|---|---|---|
| 基准年： | 2023年 | 2023/2024 年市场规模： | 525.1 亿美元 |
| 历史数据： | 2019年至2023年 | 预测期： | 2024年至2031年 |
| 预测期间 2023/2024 至 2030/2031 年复合成长率： | 18.30% | 2030/2031 价值预测： | 1700.1 亿美元 |
PD-1 和 PD-L1 抑制剂市场占有率 (%)（按地区），2024 年
PD-1和PD-L1抑制剂是免疫检查点抑制剂，在癌症治疗中显示出有希望的结果。检查点抑制剂透过阻断 PD-1 和 PD-L1 蛋白质来帮助增强人体的自然抗肿瘤反应，这些蛋白质有助于肿瘤逃避免疫系统的攻击。透过阻断这些蛋白质，检查点抑制剂使称为 T 细胞的免疫系统细胞能够更有效地识别和攻击癌细胞。近年来，多种 PD-1 和 PD-L1 抑制剂已被批准用于治疗多种癌症，如黑色素瘤、肺癌等。与传统疗法相比，这些抑制剂的临床结果有所改善，因此其市场已大幅成长，预计未来几年将出现高速成长。
市场动态：
全球PD-1和PD-L1抑制剂市场的成长是由全球癌症盛行率上升以及免疫检查点抑制剂因其有前景的临床疗效而在临床实践中越来越多的采用所推动的。此外，用于其他癌症适应症的新型 PD-1 和 PD-L1 抑制剂的批准和推出进一步推动了市场成长。然而，市场面临着开发和製造这些药物的高成本以及昂贵的定价的限制，限制了广泛采用。正在进行的临床试验评估检查点抑制剂与其他抗癌疗法相结合的潜力，从长远来看，为市场参与者提供了利润丰厚的机会。
研究的主要特点：
- 该报告对全球PD-1和PD-L1抑制剂市场进行了深入分析，并提供了以2023年为基准年的预测期（2024-2031）的市场规模和年复合成长率（CAGR%） 。
- 它阐明了不同细分市场的潜在收入机会，并解释了该市场有吸引力的投资主张矩阵。
- 这项研究还提供了有关市场驱动因素、限制因素、机会、新产品发布或批准、市场趋势、区域前景以及主要参与者采取的竞争策略的重要见解。
- 它根据以下参数（公司亮点、产品组合、主要亮点、财务业绩和策略）介绍了全球 PD-1 和 PD-L1 抑制剂市场的主要参与者。
- 该报告的见解将使行销人员和公司管理当局能够就未来的产品发布、类型升级、市场扩张和行销策略做出明智的决策。
- 全球 PD-1 和 PD-L1 抑制剂市场报告面向该行业的各个利益相关者，包括投资者、供应商、产品製造商、分销商、新进业者和财务分析师。
- 利害关係人可以透过用于分析全球 PD-1 和 PD-L1 抑制剂市场的各种策略矩阵轻鬆做出决策。
目录：
第一章：研究目标与假设
- 研究目标
- 假设
- 缩写
第 2 章：市场范围
- 报告说明
- 市场定义和范围
- 执行摘要
- Coherent Opportunity Map (COM)
第 3 章：市场动态、法规与趋势分析
- 市场动态
- 癌症发生率/盛行率上升
- 癌症治疗费用高
- 研究和开发活动的增加
- 影响分析
- 主要亮点
- 监管场景
- 产品发布/批准
- PEST分析
- 波特的分析
- 併购场景
第 4 章：全球 PD-1 和 PD-L1 抑制剂市场 - 冠状病毒 (COVID-19) 大流行的影响
- COVID-19 流行病学
- 供给面和需求面分析
- 经济影响
第 5 章：2019-2031 年全球 PD-1 和 PD-L1 抑制剂市场（按抑制剂类型）
- 介绍
- PD-1抑制剂
- PD-L1抑制剂
第 6 章：2019-2031 年全球 PD-1 和 PD-L1 抑制剂市场（按癌症类型）
- 介绍
- 肾
- 黑色素瘤
- 膀胱
- 非小细胞肺癌
- 肝
- 头颈
- 其他的
第 7 章：全球 PD-1 和 PD-L1 抑制剂市场，依配销通路，2019-2031 年
- 介绍
- 医院药房
- 零售药局
- 网路药局
第 8 章：2019-2031 年全球 PD-1 和 PD-L1 抑制剂市场（按地区）
- 介绍
- 北美洲
- 我们
- 加拿大
- 欧洲
- 英国
- 德国
- 义大利
- 法国
- 西班牙
- 俄罗斯
- 欧洲其他地区
- 亚太地区
- 中国
- 印度
- 日本
- 东协
- 澳洲
- 韩国
- 亚太地区其他地区
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地区
- 中东
- 海湾合作委员会
- 以色列
- 中东其他地区
- 非洲
- 北非
- 中非
- 南非
第 9 章：竞争格局
- Pfizer Inc.
- Novartis AG
- AstraZeneca PLC
- Gilead Sciences Inc.
- Amgen Inc.
- Sanofi AG
- F. Hoffmann-La Roche AG
- Merck & Co.
- Bristol-Myers Squibb Company
- Regeneron Pharmaceuticals Inc.
- GSK plc
- Ono Pharmaceutical Co., Ltd.
- Eli Lilly and Company
- BeiGene LTD
第 10 章：分析师观点
- 命运之轮
- 分析师观点
- 连贯的机会图
第 11 章：参考文献与研究方法
- 参考
- 研究方法论
简介目录
Product Code: CMI173
The PD-1 and PD-L1 inhibitor market is estimated to be valued at USD 52.51 Bn in 2024 and is expected to reach USD 170.01 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 18.3% from 2024 to 2031.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2023 | Market Size in 2023/2024: | US$ 52.51 Bn |
| Historical Data for: | 2019 to 2023 | Forecast Period: | 2024 to 2031 |
| Forecast Period 2023/2024 to 2030/2031 CAGR: | 18.30% | 2030/2031 Value Projection: | US$ 170.01 Bn |
PD-1 and PD-L1 Inhibitor Market Share (%), By Region, 2024
PD-1 and PD-L1 inhibitors are immune checkpoint inhibitors that have shown promising results in cancer treatment. Checkpoint inhibitors help boost the body's natural anti-tumor response by blocking proteins called PD-1 and PD-L1 that help tumors evade immune system attacks. By blocking these proteins, checkpoint inhibitors allow the immune system cells called T cells to recognize and attack cancer cells more effectively. Several PD-1 and PD-L1 inhibitors have been approved in recent years for use against various cancers like melanoma, lung cancer and more. With their improved clinical outcomes compared to conventional therapies, the market for these inhibitors has grown substantially and is expected to witness high growth in the coming years.
Market Dynamics:
The global PD-1 and PD-L1 inhibitor market growth is driven by the rising prevalence of cancer worldwide and the increasing adoption of immune checkpoint inhibitors in clinical practice due to their promising clinical efficacy. Moreover, the approval and launch of new PD-1 and PD-L1 inhibitors for additional cancer indications is further fueling the market growth. However, the market faces restraints from the high costs associated with developing and manufacturing these drugs as well as their expensive pricing which limits widespread adoption. Ongoing clinical trials evaluating the potential of combining checkpoint inhibitors with other anticancer therapies presents lucrative opportunities for market players in the long run.
Key Features of the Study:
- This report provides an in-depth analysis of the global PD-1 and PD-L1 inhibitor market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year.
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global PD-1 and PD-L1 inhibitor market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study includes Pfizer Inc., Novartis AG, AstraZeneca PLC, Gilead Sciences Inc., Amgen Inc., Sanofi AG, F. Hoffmann-La Roche AG, Merck & Co., Bristol-Myers Squibb Company, Regeneron Pharmaceuticals Inc., Merck & Co., GSK plc, Ono Pharmaceutical Co., Ltd., Eli Lilly and Company, and BeiGene LTD.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global PD-1 and PD-L1 inhibitor market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global PD-1 and PD-L1 inhibitor market.
Market Segmentation
- Type of Inhibitor:
- PD-1 Inhibitors
- PD-L1 Inhibitors
- Cancer Type:
- Kidney
- Melanoma
- Bladder
- Non-small Cell Lung Cancer
- Liver
- Head & neck
- Others
- Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
- Company Profiles:
- Pfizer Inc.
- Novartis AG
- AstraZeneca PLC
- Gilead Sciences Inc.
- Amgen Inc.
- Sanofi AG
- Hoffmann-La Roche AG
- Merck & Co.
- Bristol-Myers Squibb Company
- Regeneron Pharmaceuticals Inc.
- Merck & Co.
- GSK plc
- Ono Pharmaceutical Co., Ltd.
- Eli Lilly and Company
- BeiGene LTD
Table of Contents:
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Type of Inhibitor
- Market Snapshot, By Cancer Type
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Rise in incidence/prevalence of cancer
- High cost of cancer treatment
- Rise in research and development activities
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product launch/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
4. Global PD-1 and PD-L1 Inhibitor Market - Impact of Coronavirus (COVID-19) Pandemic
- COVID-19 Epidemiology
- Supply Side and Demand Side Analysis
- Economic Impact
5. Global PD-1 and PD-L1 Inhibitor Market, By Type of Inhibitor, 2019-2031, (US$ Bn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
- PD-1 Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
- PD-L1 Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
6. Global PD-1 and PD-L1 Inhibitor Market, By Cancer Type, 2019-2031, (US$ Bn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
- Kidney
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
- Melanoma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
- Bladder
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
- Non-small Cell Lung Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
- Liver
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
- Head & Neck
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
7. Global PD-1 and PD-L1 Inhibitor Market, By Distribution Channel, 2019-2031, (US$ Bn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
8. Global PD-1 and PD-L1 Inhibitor Market, By Region, 2019-2031, (US$ Bn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type of Inhibitor, 2019-2031, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2019-2031, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (US$ Bn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type of Inhibitor, 2019-2031, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2019-2031, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (US$ Bn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type of Inhibitor, 2019-2031, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2019-2031, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (US$ Bn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type of Inhibitor, 2019-2031, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2019-2031, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (US$ Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type of Inhibitor, 2019-2031, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2019-2031, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (US$ Bn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type of Inhibitor, 2019-2031, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2019-2031, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (US$ Bn)
- North Africa
- Central Africa
- South Africa
9. Competitive Landscape
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AstraZeneca PLC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Gilead Sciences Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Amgen Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi AG
- F. Hoffmann-La Roche AG
- Merck & Co.
- Bristol-Myers Squibb Company
- Regeneron Pharmaceuticals Inc.
- GSK plc
- Ono Pharmaceutical Co., Ltd.
- Eli Lilly and Company
- BeiGene LTD
10. Analyst View
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
11. References and Research Methodology
- References
- Research Methodology
- About us and Sales Contact
